Padcev Ejfv
Padcev Ejfv ingredients
| Active ingredient | Strength |
|---|---|
| Enfortumab Vedotin | 30 mg/3mL, 20 mg/2mL |
What Padcev Ejfv is used for
The FDA lists the approved uses on the official label (below). In the EU, enfortumab vedotin is approved as Padcev for:
Muscle invasive bladder cancer (MIBC) Padcev, in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with resectable muscle invasive bladder cancer (MIBC). Unresectable or metastatic urothelial cancer Padcev, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. Locally advanced or metastatic urothelial cancer Padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor‑1 or programmed death‑ligand 1 inhibitor (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Padcev Ejfv
- Generic name
- Enfortumab vedotin
- Made by
- SEAGEN INC.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761137
- On the US market since
- 2019
Official information
- Padcev Ejfv prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Enfortumab vedotin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Padcev Ejfv?
Padcev Ejfv (Enfortumab vedotin) is a cancer medicine made by SEAGEN INC., approved by the US FDA.
What are the ingredients of Padcev Ejfv?
Padcev Ejfv contains Enfortumab Vedotin (30 mg/3mL, 20 mg/2mL).
Is Padcev Ejfv approved in Europe?
The same active substance is approved in the EU as Padcev.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA